Will Biogen’s Qalsody Be a Catalyst for Gene-Specific ALS Research?

For Biogen, Tuesday’s FDA accelerated approval of Qalsody (tofersen) is a boon for a company in the midst of a redesign, but for superoxide dismutase 1 (SOD1) ALS patients like Todd Legg, it’s an important milestone in advancing gene-specific research for this uniformly fatal disease.